Xefo (lornoxicam) / Old API Wind-down, Takeda - LARVOL DELTA

Fragmentation-Locked Polymeric Carbon Nitride Enables Global-to-Local Electron Allocation for Enhanced Peroxymonosulfate Activation. (PubMed, Small) - "Herein, we propose a sodium-ion-locked, iodide-induced structural memory strategy to synthesize fragmented polymeric carbon nitride (NI-PCN), which enables a continuous global-to-local electron allocation pathway for boosted PMS activation. Benefiting from this structural-electronic synergism, NI-PCN achieves 98% degradation of lornoxicam (LC) within 6 min (K = 0.5751 min-1), which is 19.3 times higher than that of pristine PCN...This global-to-local electron allocation synergy facilitates O─O bond elongation and accelerates interfacial electron transfer, thus enabling efficient PMS activation. This work provides a new paradigm for the structural-electronic synergistic design of high-performance catalysts for PMS activation."

Journal

Determination of 33 non-steroidal anti-inflammatory drug residues in horse urine by QuEChERS-ultra performance liquid chromatography-tandem mass spectrometry (PubMed, Se Pu) - "The results revealed the presence of three NSAIDs， including ketorolac， lornoxicam and naproxen， with contents ranging from < LOQ to 6.87 μg/L. Lornoxicam is a banned substance and is strictly prohibited for use in horses at any time. The proposed method is simple， efficient and accurate， and is suitable for the simultaneous determination of the 33 NSAIDs residues in horse urine samples."

Journal • Inflammation • Pain

In Vitro Evaluation of Lornoxicam Liquitablets: Permeability, Anti-Inflammatory Action, Cytotoxicity, and Stability. (PubMed, Eur J Pharm Sci) - "LXM liquitablets show improved diffusion, biocompatibility, anti-inflammatory action, and long-term stability, providing strong biopharmaceutical support for clinical and regulatory development."

Journal • Preclinical • IL6 • PTGS2

AI-Assisted Pharmaceutical Formulation Design: Comparative Development and Experimental Evaluation of Sustained-Release Lornoxicam Tablets. (PubMed, Pharmaceuticals (Basel)) - "However, the magnitude of quantitative error was substantial, with RMSE values exceeding 17% and MAPE values ranging from approximately 38% to 60%. These findings indicate that the models captured general release trends but did not provide reliable quantitative dissolution predictions."

Journal • CNS Disorders • Psychiatry

Fabrication of Spanlastics as a potential transdermal delivery of lornoxicam for efficient management of osteoarthritis and side effect mitigation: Formula optimization, in vitro characterization, ex vivo, and in vivo assessments. (PubMed, Int J Pharm) - "These findings were mirrored in animals' motor performance tests and histopathological investigations, confirming the SP gel's efficacy in reducing OA deterioration without halting gastroprotective prostaglandin E2 levels. Therefore, it could be considered a promising approach for transdermal delivery of LRX for managing OA."

Adverse events • Journal • Preclinical • Immunology • Osteoarthritis • Pain • Rheumatology

Assessment of skin permeation and anti-inflammatory efficacy of Lornoxicam proniosomal topical gel formulations: a comparative study. (PubMed, Pharm Dev Technol) - "for NS, 18.7 relative to the standard gel (12.4). These findings were corroborated by anti-inflammatory efficacy studies, which revealed statistically significant improvements with the proniosomal gel (p < 0.05) compared to the standard formulation."

Journal

Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis (clinicaltrials.gov) - P=N/A | N=120 | Recruiting | Sponsor: Konya Beyhekim Training and Research Hospital

New trial • Musculoskeletal Pain • Neuralgia • Pain

Development and Evaluation of Multiple-Unit Tablets for the Controlled Release of Lornoxicam. (PubMed, Drugs R D) - "The developed biphasic-release MUTs provide rapid onset, sustained LOX delivery, and reliable dose flexibility, representing a promising oral formulation for LOX therapy."

Journal • Pain

Drug-induced upper gastrointestinal bleeding: A real-world pharmacovigilance study. (PubMed, PLoS One) - "This study conducted a pharmacovigilance analysis of drug-related UGIB by integrating and analyzing multiple adverse drug reaction databases. In both the FAERS and JADER databases, we not only identified some common risk-signaling drugs but also discovered database-specific risk-associated medications. In particular, this study performed a systematic quantitative risk assessment of the selected high-reporting-frequency drugs. This analysis not only deepened our understanding of drug risk profiles but also provided important reference evidence for clinical medication safety decision-making."

Adverse events • Journal • Real-world evidence • Gastroenterology

Transdermal Delivery of Lornoxicam via Transethosomal Gel as a Novel Strategy for Management of Rheumatoid Arthritis. (PubMed, Drug Dev Ind Pharm) - "The developed LOR-TES gel enhanced transdermal drug delivery, offering sustained release and improved permeation. It presents a promising strategy for effective management of rheumatoid arthritis through the transdermal route."

Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

The effect of methylene blue infiltrating injection on anal pain after Milligan-Morgan surgery: A randomized controlled clinical study. (PubMed, Medicine (Baltimore)) - "MBI provides effective and safe analgesia after Milligan-Morgan surgery, significantly reducing pain, analgesic consumption, hospital stay, and cost."

Clinical • Journal • Cardiovascular • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Pain • Thrombosis

Intelligent feature extraction for anaerobic/anoxic/aerobic process in municipal wastewater treatment plant. (PubMed, J Environ Sci (China)) - "Finally, the effectiveness of SAFEM is illustrated with experimental studies from a real MWWTP in China. The abnormal condition diagnosis performance of SAFEM shows that SAFEM can extract MWWTPs features accurately."

Journal

Development of machine learning predictive models for estimating pharmaceutical solubility in supercritical CO2: case study on lornoxicam solubility. (PubMed, Front Chem) - "This comparative framework illustrates the bias-variance tradeoff and offers pragmatic guidance for choosing suitable models according to dataset attributes. The methodology presents a time-efficient and cost-effective alternative to conventional thermodynamic modelling for supercritical pharmaceutical processing."

Journal

Lipid-chitosan hybrid nanoparticles for transdermal co-delivery of lornoxicam and curcumin in arthritis management. (PubMed, Int J Biol Macromol) - "These findings suggest that the developed LPHNPs are promising vehicles for the transdermal co-delivery of lornoxicam and curcumin for inflammation treatment and management. However, further investigations into the toxicity profile and subacute pharmacological effects are recommended."

Journal • Immunology • Inflammation • Rheumatology

Early application of modified A-OK protocol for amniotic fluid embolism: Case series report. (PubMed, Medicine (Baltimore)) - "These cases suggest that early A-OK-based therapy (or its modified A-GL regimen) may improve outcomes in AFE. Further research is warranted to validate this approach and refine treatment protocols."

Journal • Cardiovascular • Hematological Disorders • Obstetrics

Impact of Different Drying Processes on the Physico-Chemical Properties of Liquitablet Formulations Containing Lornoxicam. (PubMed, Pharmaceutics) - "A similarity was observed between our freeze-dried product and the marketed fast-release tablets. This research demonstrates that preparation of liquitablet in combination with freeze-drying has a significantly positive effect in improving the in vitro dissolution rate of lornoxicam."

Journal

Lipid Raft Membrane Interactivity Correlating with Cyclooxygenase-2 Selectivity of Non-Steroidal Anti-Inflammatory Drugs. (PubMed, Membranes (Basel)) - "Conventional NSAIDs (diclofenac, ibuprofen, indomethacin, aspirin, and flurbiprofen) and Coxibs (lumiracoxib, etoricoxib, celecoxib, valdecoxib, and rofecoxib) decreased membrane fluidity, whereas Oxicams (meloxicam, piroxicam, tenoxicam, and lornoxicam) increased. Under inflammatory acidic conditions, the lipid raft membrane interactivity of NSAIDs was more likely to correlate with cyclooxygenase-2 selectivity than the reference membrane interactivity. It is hypothesized that NSAIDs may interact with lipid raft membranes to induce membrane fluidity changes with the potency corresponding to cyclooxygenase-2 inhibition, disrupting the structural and functional integrity of lipid rafts to affect the activity of cyclooxygenase-2 localized in lipid rafts, resulting in cyclooxygenase-2 selective inhibition."

Journal

RETRACTION: Safety and Efficacy of Pre-Incisional Peritonsillar Lornoxicam in Paediatric Post-Tonsillectomy Pain: A Prospective Double-Blind, Placebo-Controlled, Split-Body Clinical Study. (PubMed, Clin Otolaryngol) - "Therefore, the parties agree that the article must be retracted. The authors disagree with the retraction."

Journal • Otorhinolaryngology • Pain • Pediatrics

Antithrombotic potential of lornoxicam and possible mechanistic pathways. (PubMed, J Pharmacol Exp Ther) - "SIGNIFICANCE STATEMENT: The in silico, in vitro, and in vivo experiments in this study revealed the excellent antithrombotic potential and protective effect of lornoxicam on myocardial infarction and pulmonary embolism, even at lower doses. This study proposes that lornoxicam treatment, just like aspirin, at lower doses could be an appropriate prophylactic option in patients who are more prone to myocardial infarction and pulmonary embolism."

Journal • Cardiovascular • Hematological Disorders • Myocardial Infarction • Oncology • Pain • Pulmonary Embolism • Respiratory Diseases • TNFA

An injectable ropivacaine and lornoxicam sustained-release gel regulated by low molecular weight poly(ortho esters). (PubMed, Pharm Dev Technol) - "Compared to commercial products, RL-SRG prolonged the time of peak concentration (Tmax), mean residence time (MRT), and elimination half-life (t1/2), as well as possessed similar the area under the plasma concentration-time curve (AUC0-t). Therefore, RL-SRG has been validated as a novel sustained release system to the application for the long-term treatment of postoperative pain."

Journal • Anesthesia • Pain

Application of particle swarm optimization to non-orthogonal error correction in SAFEM total magnetic intensity measurements. (PubMed, Rev Sci Instrum) - "Experiments with a physical measurement system further validated the method's efficacy: after calibration, the maximum absolute error and the RMSE of the TMI were significantly reduced by 82.84% and 87.64%, respectively. This study provides a critical technical solution for the complex, multi-parameter error calibration of alternating current vector magnetometers, ensuring the acquisition of high-precision TMI data for SAFEM systems."

Journal

Comprehensive Analysis of Gastrointestinal Injury Induced by Nonsteroidal Anti-Inflammatory Drugs Using Data from FDA Adverse Event Reporting System Database. (PubMed, Pharmaceuticals (Basel)) - "Cyclooxygenase-2 (COX-2) selective NSAIDs (e.g., celecoxib, rofecoxib) were associated with a lower incidence but greater severity, primarily in the upper GI tract. Conversely, nonselective NSAIDs (e.g., acetylsalicylic acid, lornoxicam) showed higher incidence rates, though the events were generally milder. In our dataset, acetylsalicylic acid had the highest incidence, whereas meloxicam showed the highest severity... NSAIDs differ significantly in their gastrointestinal adverse event profiles, attributable to COX selectivity. When selecting an NSAID, both the likelihood and the nature of potential GI harm should be considered."

Adverse events • Journal • Gastroenterology • Gastrointestinal Disorder

Postoperative analgesic efficacy of preemptive and postoperative lornoxicam in femoropopliteal bypass surgery. (PubMed, Agri) - "Regardless of the time it is applied, lornoxicam reduces postoperative pain and consumption of opioids within the initial 3 hours."

Journal • Pain

Influence of Orange Oil on Skin Permeability, Dermatokinetics, and In Vivo Anti-inflammatory Properties of Lornoxicam-loaded Niosomal Gel. (PubMed, Curr Drug Metab) - "The study concluded that orange oil enhanced skin permeability and influenced the derma-tokinetics of the LOR-OR-NIO gel, leading to an improvement in in vivo anti-inflammatory properties."

Journal • Preclinical

Comparative study of the efficacy and safety of combined therapy with lornoxicam (Xefokam Rapid) and a nucleotide complex Xefomielyn in patients with exacerbation of chronic nonspecific low back pain (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "The data obtained indicate high clinical efficacy and a favorable safety profile of combination therapy with Xefocam Rapid and Xefomyelin in patients with CLBP."

Clinical • Journal • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain